EMA Withdrawn: Quixidar (fondaparinux sodium) — Glaxo Group Ltd.

View source ↗

Summary

The EMA indicates withdrawal of Quixidar (fondaparinux sodium) from the market by Glaxo Group Ltd., covering indications including venous thrombosis, pulmonary …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction
• Pulmonary Embolism
• Unstable Angina
• Venous Thrombosis

Drugs mentioned

• Quixidar (fondaparinux sodium)

Snippet

Status: Withdrawn. Therapeutic area: Venous Thrombosis;Pulmonary Embolism;Myocardial Infarction;Angina, Unstable. MAH: Glaxo Group Ltd.. Decision date: 24/10/2007